In honour of Prostate Cancer Awareness Month, Dr. Laurence Klotz, MD, FCRPC, and pioneer of Active Surveillance will be joining us for our September meeting. Don't miss out on this opportunity to chat with Canada's leading expert in Active Surveillance.
This new nationwide Active Surveillance support group aims to bring together prostate cancer patients and advocates who will empower men newly diagnosed with low-risk and intermediate prostate cancer by providing them with the latest information to help them make informed decisions with their physicians regarding approaches to active surveillance.
About Laurence Klotz, CM, MD, FRCSC:
Dr. Klotz is a widely published uro-oncologist (504 peer review publications, 6 books). His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy. He has led numerous randomized trials in prostate cancer.
Active surveillance was a concept pioneered under Dr. Klotz’s leadership. He led the team at Sunnybrook who was the first to implement an approach to patients with low risk prostate cancer based on conservative management, with selective intervention for those patients who were diagnosed as higher risk over time. He coined the term ‘active surveillance’, and was responsible for promoting its acceptance by urological and radiation oncology communities worldwide. His drive to reduce the overtreatment, morbidity, and mortality of prostate cancer has led to over a hundred papers on this subject alone and numerous national and international invitations as a guest lecturer and visiting professor.